Eculizumab (Soliris®)

DRUG2 trials

Sponsors

Alexion Pharmaceuticals, Inc., Massachusetts General Hospital

Conditions

NMOSDShiga-like Toxin-producing Escherichia Coli

Phase 2

Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)

CompletedNCT01410916

Alexion Pharmaceuticals, Inc.Shiga-like Toxin-producing Escherichia Coli

Start: 2011-07-31End: 2012-06-30Updated: 2013-04-05

Phase 4

Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

Not yet recruitingNCT07010302

Massachusetts General HospitalNMOSD

Start: 2026-05-01End: 2030-05-01Target: 540Updated: 2026-03-16